Pierre-Olivier is passionate about innovation in the field of health. For more than 20 years, he has accompanied, co-founded and managed numerous companies providing new therapeutic solutions in order to better treat patients. He has succeeded in signing numerous licensing and partnership agreements with major players in the life sciences, and in raising funds from professional investors and public markets.
He was notably co-founder and director of Erytech Pharma, Chairman of Axoltis and Chairman of France Biotech, the French association of innovative companies in the life sciences.Pierre-Olivier holds a Master Degree in Strategy & Finance, and another one in Management of Pharmaceutical Industry from IAE Lyon University.
Ana Hennino is at the origin of the project, she completed her PhD as an ENS student in Immunology at the INSERM in Lyon in 2001. She developed during PhD studies expertise in molecular mechanisms involved in apoptosis in B cell compartment and identified c-FLIP as a key regulator of the apoptosis of B cells in the germinal center.
Through her post-doctoral studies in the field of immunology of allergy she demonstrated an important role of the CD8+ T cell response at the initiation of the skin-allergic immune response. Since 2014, her research in CancerResearch Center Lyon focuses on the regulation of the immune response by the stromal compartment in the context of autoimmunity and cancer.
Eric is an expert in early clinical development and helps Stromacare to fine tune its clinical pathway. He is head of medical oncology at Groupe Hospitalier Paris Saint-Joseph since 2016.
He spent all his carrier in oncology department of prestigious hospitals : Lausanne Hospital, Beaujon Paris Hospital, Saint-Louis Paris Hospital, IGR Paris. He is MD and holds a PhD in Molecular Biology from Pierre et Marie Curie Paris University.
Mrs. Karine Aguerra is Program Director.
Karine has worked for more than 15 years in the field of biotechnology in project management. She oversaw all the coordination of a major program involving the regulatory authorities, and the medical, pharmaceutical, quality control and R&D teams.
She likes to work cross-functionally with teams from different professional cultures, both internally and externally. Her rigor and her ability to gather information, to mobilize stakeholders, to meet deadlines are decisive for StromaCare where she will be in charge of all the management of the development project of our Lead as well as the editorial parts R&D and toxicity of the regulatory files.
Sophie Bachy is a research engineer. She has worked for the past few years in the Inserm laboratory led by Ana Hennino and has carried out a large number of the experiments that make up the POC
.
She has extensive experience in research and development acquired in many companies, for example Valneva.
Pierre-Olivier is passionate about innovation in the field of health. For more than 20 years, he has accompanied, co-founded and managed numerous companies providing new therapeutic solutions in order to better treat patients. He has succeeded in signing numerous licensing and partnership agreements with major players in the life sciences, and in raising funds from professional investors and public markets.
He was notably co-founder and director of Erytech Pharma, Chairman of Axoltis and Chairman of France Biotech, the French association of innovative companies in the life sciences.Pierre-Olivier holds a Master Degree in Strategy & Finance, and another one in Management of Pharmaceutical Industry from IAE Lyon University.
Ana Hennino is at the origin of the project, she completed her PhD as an ENS student in Immunology at the INSERM in Lyon in 2001. She developed during PhD studies expertise in molecular mechanisms involved in apoptosis in B cell compartment and identified c-FLIP as a key regulator of the apoptosis of B cells in the germinal center.
Through her post-doctoral studies in the field of immunology of allergy she demonstrated an important role of the CD8+ T cell response at the initiation of the skin-allergic immune response. Since 2014, her research in CancerResearch Center Lyon focuses on the regulation of the immune response by the stromal compartment in the context of autoimmunity and cancer.
Mrs. Karine Aguerra is Program Director.Karine has worked for more than 15 years in the field of biotechnology in project management. She oversaw all the coordination of a major program involving the regulatory authorities, and the medical, pharmaceutical, quality control and R&D teams.
She likes to work cross-functionally with teams from different professional cultures, both internally and externally. Her rigor and her ability to gather information, to mobilize stakeholders, to meet deadlines are decisive for StromaCare where she will be in charge of all the management of the development project of our Lead as well as the editorial parts R&D and toxicity of the regulatory files.
Eric is an expert in early clinical development and helps Stromacare to fine tune its clinical pathway. He is head of medical oncology at Groupe Hospitalier Paris Saint-Joseph since 2016.
He spent all his carrier in oncology department of prestigious hospitals : Lausanne Hospital, Beaujon Paris Hospital, Saint-Louis Paris Hospital, IGR Paris. He is MD and holds a PhD in Molecular Biology from Pierre et Marie Curie Paris University.
José has spent the last 25 years in biotech companies working, among others, as Director of Quality Assurance, Director of Nonclinical studies, and Director of Clinical studies. He has also led a project up to Phase 3 clinical trial.
He has a broad experience in biological drugs development, from biomanufacturing to clinical trial operations. In its last position, he has set up and managed the Quality Management System for both internal research activities and for GxP subcontracted activities that has allowed to release more than 10 different Investigational Medicinal Products for clinical trials (Phase 1 to Phase 3).
